| LDR | 01220nam a2200265 a 4500 | ||
| 001 | 007609945 | ||
| 003 | MiAaHDL | ||
| 005 | 20130605000000.0 | ||
| 006 | m d | ||
| 007 | cr bn ---auaua | ||
| 008 | 870922s1987 xxuak b f000 0 eng d | ||
| 010 | ⊔ | ⊔ | ‡a 87600903 |
| 035 | ⊔ | ⊔ | ‡asdr-pst.a897481 |
| 035 | ⊔ | ⊔ | ‡asdr-ucr.b19410426 |
| 035 | ⊔ | ⊔ | ‡a(OCoLC)15267926 |
| 035 | ⊔ | ⊔ | ‡aLIAS1280092 |
| 040 | ⊔ | ⊔ | ‡cPSt ‡dWaOLN |
| 050 | 0 | ⊔ | ‡aKF27 ‡b.G664 1986e |
| 074 | ⊔ | ⊔ | ‡a1016-A, 1016-B (microfiche) |
| 086 | 0 | ⊔ | ‡aY 4.G 74/7:D 84/21 |
| 110 | 1 | ⊔ | ‡aUnited States. ‡bCongress. ‡bHouse. ‡bCommittee on Government Operations. ‡bIntergovernmental Relations and Human Resources Subcommittee. |
| 245 | 1 | 0 | ‡aOversight of the new drug review process and FDA's regulation of Merital : ‡bhearing before a subcommittee of the Committee on Government Operations, House of Representatives, Ninety-ninth Congress, second session, May 22, 1986. |
| 260 | ⊔ | ⊔ | ‡aWashington : ‡bU.S. G.P.O. : ‡bFor sale by the Supt. of Docs., Congressional Sales Office, U.S. G.P.O., ‡c1987. |
| 300 | ⊔ | ⊔ | ‡aiii, 529 p. : ‡bill., forms ; ‡c24 cm. |
| 504 | ⊔ | ⊔ | ‡aIncludes bibliographies. |
| 538 | ⊔ | ⊔ | ‡aMode of access: Internet. |
| 610 | 1 | 0 | ‡aUnited States. ‡bFood and Drug Administration. |
| 650 | ⊔ | 0 | ‡aNomifensine. |
| 650 | ⊔ | 0 | ‡aPharmacy ‡xLaw and legislation ‡zUnited States. |
| 650 | ⊔ | 0 | ‡aDrugs ‡xLaw and legislation ‡zUnited States. |
| CID | ⊔ | ⊔ | ‡a007609945 |
| DAT | 0 | ⊔ | ‡b20130605000000.0 |
| DAT | 1 | ⊔ | ‡a20130709225806.0 ‡b2023-11-28T19:05:02Z |
| DAT | 2 | ⊔ | ‡a2023-11-28T18:30:02Z |
| CAT | ⊔ | ⊔ | ‡aSDR-PST ‡dUNKNOWN ‡lloader.pl-002-002 |
| FMT | ⊔ | ⊔ | ‡aBK |
| HOL | ⊔ | ⊔ | ‡0sdr-pst.a897481 ‡apst ‡bSDR ‡cPST ‡ppst.000012650576 ‡sPST ‡z4.G 74/7:D 84/21 ‡1a897481 |
| 974 | ⊔ | ⊔ | ‡bPST ‡cPST ‡d20231128 ‡sgoogle ‡upst.000012650576 ‡z4.G 74/7:D 84/21 ‡y1987 ‡rpd ‡qbib ‡tUS fed doc |
| 974 | ⊔ | ⊔ | ‡bUC ‡cUCR ‡d20240505 ‡sgoogle ‡uuc1.31210012721443 ‡y1987 ‡rpd ‡qbib ‡tUS fed doc |